Glaucoma Service, Moorfields Eye Hospital NHS Foundation Trust, London, UK; UCL Institute of Ophthalmology, London, UK; National Institute for Health and Care Research Moorfields Biomedical Research Centre, London, UK.
Copenhagen University Hospital, Rigshospitalet, Glostrup, Denmark; University of Copenhagen, Department of Drug Design and Pharmacology, Copenhagen, Denmark.
Lancet. 2023 Nov 11;402(10414):1788-1801. doi: 10.1016/S0140-6736(23)01289-8. Epub 2023 Sep 21.
The glaucomas are a group of conditions leading to irreversible sight loss and characterised by progressive loss of retinal ganglion cells. Although not always elevated, intraocular pressure is the only modifiable risk factor demonstrated by large clinical trials. It remains the leading cause of irreversible blindness, but timely treatment to lower intraocular pressure is effective at slowing the rate of vision loss from glaucoma. Methods for lowering intraocular pressure include laser treatments, topical medications, and surgery. Although modern surgical innovations aim to be less invasive, many have been introduced with little supporting evidence from randomised controlled trials. Many cases remain undiagnosed until the advanced stages of disease due to the limitations of screening and poor access to opportunistic case finding. Future research aims to generate evidence for intraocular pressure-independent neuroprotective treatments, personalised treatment through genetic risk profiling, and exploration of potential advanced cellular and gene therapies.
青光眼是一组导致不可逆转视力丧失的疾病,其特征是视网膜神经节细胞进行性丧失。尽管并非总是升高,但大量临床试验证明,眼内压是唯一可改变的危险因素。它仍然是不可逆性失明的主要原因,但及时降低眼内压的治疗可以有效减缓青光眼导致的视力丧失速度。降低眼内压的方法包括激光治疗、局部药物治疗和手术。尽管现代手术创新旨在减少创伤,但许多创新方法都没有随机对照试验的证据支持。由于筛查的局限性和机会性病例发现的机会有限,许多病例直到疾病的晚期才被诊断出来。未来的研究旨在为眼压无关的神经保护治疗、通过遗传风险分析进行个性化治疗以及探索潜在的先进细胞和基因治疗提供证据。